In order to confirm the above findings in cancer patients, 18 PD-L1-positive HCC patients injected with PD-1 mAb, comprising ten responders, and eight non-responders (Table S4), were recruited for the analysis of GZMA and F2R expressions. The gene discussed is CD274; the disease is cancer.